• Wion
  • /World
  • /Australian man becomes first in world to leave hospital with a completely artificial heart

Australian man becomes first in world to leave hospital with a completely artificial heart

Australian man becomes first in world to leave hospital with a completely artificial heart

Story highlights

World | Explore the future of cardiac care with the BiVacor heart, aiming for patients to live without transplants, powered by a portable controller for seamless integration.

In a first, an Australian man became the first patient in the world to be discharged from a hospital fitted with a completely artificial heart. The man, who is reportedly in his 40s, received an artificial heart surgery after he suffered from severe heart failure.

The artificial heart, called BiVacor Total Artificial Heart, was given to him after he suffered from severe heart failure at St Vincent's Hospital Sydney last November.

Add WION as a Preferred Source

The BiVacor Total Artificial Heart is a groundbreaking medical device designed to replace a failing heart in patients with end-stage heart failure.

This artificial heart is made from titanium, ensuring high biocompatibility, corrosion resistance, and strength. The BiVacor Total Artificial Heart features a single, magnetically levitating rotor that pumps blood to the lungs and the rest of the body.

In a statement, St Vincent's said, "The patient holds the record for the longest time a BiVacor patient has gone from implant to transplant – a major step toward the future of artificial heart technology."

With this innovation, the long-term goal is for patients to live with the device indefinitely without needing a transplant," the hospital added.

BiVacor Total Artificial Heart device has two separate pump chambers, each with a unique impeller design, allowing for efficient blood flow. Also, the device is powered by a small, external, and portable controller that exits through the stomach.

The BiVacor Total Artificial Heart has undergone successful implantation in a first-in-human clinical trial, with the first patient receiving the device in July 2024.

The trial aims to evaluate the safety and performance of the device as a bridge-to-transplant solution for patients with severe biventricular heart failure.

(With inputs from agencies)